[HTML][HTML] Could we predict the response of immune checkpoint inhibitor treatment in hepatocellular carcinoma?
Simple Summary The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is now
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
CK Lee, SL Chan, HJ Chon - Cancers, 2022 - europepmc.org
The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is an important strategy
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
L Choong-kun, SL Chan, HJ Chon - Cancers, 2022 - search.proquest.com
The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is an important strategy
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
CK Lee, SL Chan, HJ Chon - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is an important strategy
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10-20% of …
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10-20% of …
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
C Lee, SL Chan, HJ Chon - Cancers, 2022 - search.ebscohost.com
Abstract Simple Summary: The use of anti-programmed cell-death protein (ligand)-1 (PD-[L]
1) is now a standard of care for treating hepatocellular carcinoma (HCC). However, the …
1) is now a standard of care for treating hepatocellular carcinoma (HCC). However, the …
[HTML][HTML] Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
C Lee, SL Chan, HJ Chon - Cancers, 2022 - ncbi.nlm.nih.gov
The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is an important strategy
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …
for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20 …